Inozyme Pharma (INZY) Q3 2024 earnings summary

Executive summary

• Advanced INZ-701 clinical trials in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, with positive interim data from SEAPORT 1 and ENERGY 1 trials and new regulatory milestones achieved.

• Announced FDA Fast Track designation for INZ-701 in ABCC6 Deficiency and presented new data at major industry meetings.

• Appointed Erik Harris to the Board, bringing significant commercial expertise.

• Launch of the PROPEL Registry to study ENPP1 and ABCC6 Deficiency disease burden.

Financial highlights

• Net loss of $24.6 million ($0.39 per share) for Q3 2024, compared to $16.6 million ($0.29 per share) in Q3 2023.

• Net loss of $75.0 million ($1.20 per share) for the nine months ended September 30, 2024, up from $49.6 million ($1.02 per share) year-over-year.

• Operating expenses rose to $24.9 million in Q3 2024 from $18.1 million in Q3 2023, driven by increased R&D spending.

• Cash, cash equivalents, and short-term investments totaled $131.6 million as of September 30, 2024.

• Net proceeds of $10.4 million raised from at-the-market equity sales during the period.

Outlook and guidance

• Cash and investments expected to fund operations into Q4 2025 based on current plans.

• Plans to initiate pivotal/registrational trials for INZ-701 in calciphylaxis and ABCC6 Deficiency in 2025, subject to regulatory review and funding.

• ENERGY 3 pivotal trial in pediatric ENPP1 Deficiency to complete enrollment by end of 2024; topline data in early 2026.

• ENERGY 2 pivotal trial in infants with ENPP1 Deficiency to initiate outside the US in Q4 2024.